TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today announced that they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction (the “Transaction”).

多伦多和埃德蒙顿，2023年12月14日（环球通讯社）--Aeterna Zentaris Inc.（纳斯达克：AEZS）（TSX:AEZS）（“Aeterna”）和Ceapro Inc.（TSXV:CZO）（OTCQX:CRPOF）（“Ceapro”）两家创新的生物制药开发公司今天宣布，他们已经签署了一项最终协议，以平等交易的全股票合并（“交易”）方式合并运营。

The combined company is expected to be listed on the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange (the “TSX”), subject to the receipt of all necessary approvals. A new name for the combined company will be announced in the coming weeks and the Transaction is expected to close in the first quarter of 2024.

合并后的公司预计将在纳斯达克资本市场（“Nasdaq”）和多伦多证券交易所（“TSX”）上市，但须获得所有必要的批准。合并后的公司将在未来几周宣布新名称，交易预计将于2024年第一季度完成。

The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels. Key attributes of the combined company include: Recurring revenue to support business expansion.

这一合并对两家公司的股东都很有吸引力，因为它有望创造一个长期可持续的业务，随着生物制药行业从目前的水平恢复，该业务的最佳定位是提供价值。合并公司的关键属性包括：支持业务扩张的经常性收入。

The combined company will benefit from ongoing revenue from existing Ceapro products – which provide near-term revenue owing to the streamlined development and commercialization opportunities in the cosmeceutical and nutraceutical space – along with license revenue from the partnering of Aeterna’s pharmaceutical products, including Macrilen®/Ghryvelin®, which have the potential to create long-term value for investors.

合并后的公司将受益于现有Ceapro产品的持续收入，这些产品由于在药妆和营养保健领域的简化开发和商业化机会而提供了近期收入，以及Aeterna制药产品（包括Macrilen®/Ghryvelin®）合作产生的许可收入，有可能为投资者创造长期价值。

These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors. Diversified commercial and development product pipeline. The combined company will have a stronghold in the active ingredients market and value-driving cosmeceutical products .

这些收入流将用于支持高潜在回报产品的开发，并为投资者提供更加多样化的价值主张。多样化的商业和开发产品线。合并后的公司将在活性成分市场和价值驱动的药妆产品中拥有据点。